EUVIMEDEUVIMED entdecken
Metaanalyse

Vancomycin Plus Piperacillin–Tazobactam Versus Vancomycin Plus Cefepime and the Risk of Acute Kidney Injury in Hospitalised Adults: A Meta-Analysis

Putri Indah Permata, Deka Viotra

Sriwijaya Journal of Internal Medicine · 03.06.2026 · 4 (1) · 30-38

DOI: 10.59345/sjim.v4i1.267 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Sriwijaya Journal of Internal Medicine, online erschienen am 03.06.2026. Verfasst von Putri Indah Permata und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The combination of vancomycin and piperacillin–tazobactam is among the most frequently prescribed empirical regimens for serious infections, yet observational data suggest that it may increase the risk of acute kidney injury (AKI). Because vancomycin is common to many comparisons, the cleanest test of the piperacillin–tazobactam effect is a head-to-head comparison against vancomycin plus cefepime, in which vancomycin exposure is held constant. This meta-analysis quantified the association between the two regimens and AKI in hospitalised adults.

Methods

PubMed/MEDLINE, Scopus and Web of Science were searched for comparative cohort studies and randomised trials in adults reporting AKI with vancomycin plus piperacillin–tazobactam versus vancomycin plus cefepime. Two regimens were compared. Risk of bias was appraised with ROBINS-I. Odds ratios (OR) were pooled using a DerSimonian–Laird random-effects model; heterogeneity was summarised with the I² statistic, and small-study effects were examined with the Egger test and a leave-one-out sensitivity analysis.

Results

Ten cohort studies were eligible and nine contributed to the quantitative synthesis. Vancomycin plus piperacillin–tazobactam was associated with significantly higher odds of AKI than vancomycin plus cefepime (pooled OR 1.90, 95% CI 1.43–2.52; p

Zitieren

APA

Permata, P. I., & Viotra, D. (2026). Vancomycin Plus Piperacillin–Tazobactam Versus Vancomycin Plus Cefepime and the Risk of Acute Kidney Injury in Hospitalised Adults: A Meta-Analysis. Sriwijaya Journal of Internal Medicine, 4(1), 30-38. https://doi.org/10.59345/sjim.v4i1.267

Vancouver

Permata PI, Viotra D. Vancomycin Plus Piperacillin–Tazobactam Versus Vancomycin Plus Cefepime and the Risk of Acute Kidney Injury in Hospitalised Adults: A Meta-Analysis. Sriwijaya Journal of Internal Medicine. 2026;4(1):30-38. doi:10.59345/sjim.v4i1.267

BibTeX
@article{Permata2026,
  author = {Permata, Putri Indah and Viotra, Deka},
  title = {Vancomycin Plus Piperacillin–Tazobactam Versus Vancomycin Plus Cefepime and the Risk of Acute Kidney Injury in Hospitalised Adults: A Meta-Analysis},
  journal = {Sriwijaya Journal of Internal Medicine},
  year = {2026},
  volume = {4},
  number = {1},
  pages = {30--38},
  doi = {10.59345/sjim.v4i1.267}
}
Kostenlos starten →